UNSPSC 51384505: Cinaproxen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1J0E0I69E9. European Medicines Agency schedules Cinaproxen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06286MIG. Cinaproxen generally arises in the molecular formula C19H21NO5S.

UNSPSC 51384505 Cinaproxen is a Commodity code that covers pharmaceutical products, but state and local procurement activity under this specific code does not cleanly match the nominal category. Recent opportunities tagged to this code reflect a much broader scope: state and local governments are procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participants across multiple states including Oregon). These jurisdictions are buying pharmaceutical supply, not the specific compound implied by the code name.

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2026, through an electronic bidding process with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; vendors must work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and meet cGMP and Drug Supply Chain Security Act certifications. The code itself shows limited alignment with the recent opportunities being procured; activity centers on broader pharmaceutical procurement rather than the specific compound.